Trial Profile
Dose-finding study of olaparib in women with breast cancer who were scheduled to undergo elective surgery
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2013
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Early breast cancer
- Focus Biomarker; Pharmacodynamics
- 17 Apr 2013 New trial record
- 18 Feb 2008 Primary endpoint 'Recommended-phase-II-dose' has not been met.